TaiRx Quick Ratio

What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.